Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

Cephalon100 enrolled

Overview

The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Pain Cancer

Interventions

OraVescent fentanyl (OVF)DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Documented diagnosis of a malignant solid tumor or hematological malignancy causing cancer related pain * Currently taking around the clock opioid therapy for pain * Experience on average, 1-4 breakthrough pain episodes per day Exclusion Criteria: * Opioid or fentanyl intolerance * Sleep apnea or active brain metastases with increased intracranial pressure * COPD (chronic obstructive pulmonary disease); cardiopulmonary disease; heart disease

Locations (26)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.